288 related articles for article (PubMed ID: 1281055)
21. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
23. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
Chen X; Shen D; Sun T; Bai J; Huang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
[TBL] [Abstract][Full Text] [Related]
24. Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor D-1-methyl-tryptophan.
Zhang X; Yang Y; Zhang L; Lu Y; Zhang Q; Fan D; Zhang Y; Zhang Y; Ye Z; Xiong D
J Hematol Oncol; 2017 Feb; 10(1):56. PubMed ID: 28228105
[TBL] [Abstract][Full Text] [Related]
25. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
26. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
[TBL] [Abstract][Full Text] [Related]
27. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
[TBL] [Abstract][Full Text] [Related]
28. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes.
Löffler A; Kufer P; Lutterbüse R; Zettl F; Daniel PT; Schwenkenbecher JM; Riethmüller G; Dörken B; Bargou RC
Blood; 2000 Mar; 95(6):2098-103. PubMed ID: 10706880
[TBL] [Abstract][Full Text] [Related]
29. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.
Hoffmann P; Hofmeister R; Brischwein K; Brandl C; Crommer S; Bargou R; Itin C; Prang N; Baeuerle PA
Int J Cancer; 2005 May; 115(1):98-104. PubMed ID: 15688411
[TBL] [Abstract][Full Text] [Related]
30. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC
J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277
[TBL] [Abstract][Full Text] [Related]
31. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.
Kipriyanov SM; Moldenhauer G; Strauss G; Little M
Int J Cancer; 1998 Aug; 77(5):763-72. PubMed ID: 9688311
[TBL] [Abstract][Full Text] [Related]
32. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
33. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
34. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
35. Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.
Pupa SM; Canevari S; Fontanelli R; Ménard S; Mezzanzanica D; Lanzavecchia A; Colnaghi MI
Int J Cancer; 1988 Sep; 42(3):455-9. PubMed ID: 2971021
[TBL] [Abstract][Full Text] [Related]
36. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells.
Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852
[TBL] [Abstract][Full Text] [Related]
37. Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.
Möller SA; Reisfeld RA
Cancer Immunol Immunother; 1991; 33(4):210-6. PubMed ID: 1647871
[TBL] [Abstract][Full Text] [Related]
38. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody.
Dreier T; Lorenczewski G; Brandl C; Hoffmann P; Syring U; Hanakam F; Kufer P; Riethmuller G; Bargou R; Baeuerle PA
Int J Cancer; 2002 Aug; 100(6):690-7. PubMed ID: 12209608
[TBL] [Abstract][Full Text] [Related]
39. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
40. Further characterization of cytotoxic T cells generated by short-term culture of human peripheral blood lymphocytes with interleukin-2 and anti-CD3 mAb.
Jacobs N; Greimers R; Mazzoni A; Trebak M; Schaaf-Lafontaine N; Boniver J; Moutschen MP
Cancer Immunol Immunother; 1996 Jul; 42(6):369-75. PubMed ID: 8830741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
